Education
About Us
Working with TipRanks
Follow Us
Check-Cap (CHEK)
NASDAQ:CHEK
CHEK Stock Chart & Stats
$1.71
-$0.22(-13.41%)
At close: 4:00 PM EST
$1.71
-$0.22(-13.41%)
Day’s Range― - ―
52-Week Range$0.56 - $3.13
Previous CloseN/A
Volume282.32K
Average Volume (3M)5.95M
Market Cap
$9.13M
Enterprise ValueN/A
Total Cash (Recent Filing)$265.00K
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding7,020,502
10 Day Avg. Volume179,340
30 Day Avg. Volume5,951,576
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-3.99
Price to Sales (P/S)0.00
P/FCF Ratio-723.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Check-Cap News
CHEK FAQ
What was Check-Cap’s price range in the past 12 months?
Check-Cap lowest stock price was $0.56 and its highest was $3.13 in the past 12 months.
What is Check-Cap’s market cap?
Check-Cap’s market cap is $9.13M.
When is Check-Cap’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Check-Cap’s earnings last quarter?
Currently, no data Available
Is Check-Cap overvalued?
According to Wall Street analysts Check-Cap’s price is currently Overvalued.
Does Check-Cap pay dividends?
Check-Cap does not currently pay dividends.
What is Check-Cap’s EPS estimate?
Check-Cap’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Check-Cap have?
Check-Cap has 7,020,502 shares outstanding.
What happened to Check-Cap’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Check-Cap?
Currently, no hedge funds are holding shares in CHEK
Company Description
Check-Cap
Check-Cap Ltd. is a medical technology company that focuses on the development of C-Scan, an ingestible capsule-based system designed to detect polyps before they may transform into colorectal cancer. The company operates within the healthcare and medical device sectors, aiming to provide a patient-friendly, preparation-free screening option for colorectal cancer, enhancing early detection and prevention efforts.
Technical Analysis
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.17% Mutual Funds
<0.01% Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---